{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:46:37Z","timestamp":1773657997090,"version":"3.50.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2008,10,31]],"date-time":"2008-10-31T00:00:00Z","timestamp":1225411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0003593","type":"journal-article","created":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T14:10:55Z","timestamp":1225375855000},"page":"e3593","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Growth Arrest of BCR-ABL Positive Cells with a Sequence-Specific Polyamide-Chlorambucil Conjugate"],"prefix":"10.1371","volume":"3","author":[{"given":"C. James","family":"Chou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"O'Hare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Eide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Gottesfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2008,10,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.","volume":"243","author":"JD Rowley","year":"1973","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia.","volume":"340","author":"CL Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"ref3","first-page":"2049","article-title":"BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.","volume":"60","author":"MW Deininger","year":"2000","journal-title":"Cancer Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"BJ Druker","year":"1996","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"BJ Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.","volume":"110","author":"T O'Hare","year":"2007","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.","volume":"100","author":"OG Ottmann","year":"2002","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.","volume":"99","author":"CL Sawyers","year":"2002","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.","volume":"99","author":"M Talpaz","year":"2002","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.","volume":"305","author":"NP Shah","year":"2004","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","volume":"65","author":"T O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.leu.2402531","article-title":"Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.","volume":"16","author":"T Robak","year":"2002","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/10428190310001595704","article-title":"High dose chlorambucil in the treatment of lymphoid malignancies.","volume":"45","author":"A Nicolle","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0968-0896(97)00096-5","article-title":"Structure-activity relationship of a series of C-terminus modified aminoalkyl, diaminoalkyl- and anilino-containing analogues of the benzoic acid mustard distamycin derivative tallimustine: synthesis, DNA binding and cytotoxicity studies.","volume":"5","author":"N Brooks","year":"1997","journal-title":"Bioorg Med Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1021\/jm040790d","article-title":"Design and synthesis of a nitrogen mustard derivative stabilized by apo-neocarzinostatin.","volume":"47","author":"MD Urbaniak","year":"2004","journal-title":"J Med Chem"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1074-5521(00)00085-5","article-title":"Sequence specific alkylation of DNA by hairpin pyrrole-imidazole polyamide conjugates.","volume":"7","author":"NR Wurtz","year":"2000","journal-title":"Chem Biol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1021\/ja029196o","article-title":"Inhibition of transcription at a coding sequence by alkylating polyamide.","volume":"125","author":"T Oyoshi","year":"2003","journal-title":"J Am Chem Soc"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1021\/ja031673v","article-title":"Sequence-specific gene silencing in mammalian cells by alkylating pyrrole-imidazole polyamides.","volume":"126","author":"K Shinohara","year":"2004","journal-title":"J Am Chem Soc"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.chembiol.2004.09.004","article-title":"Arresting cancer proliferation by small-molecule gene regulation.","volume":"11","author":"LA Dickinson","year":"2004","journal-title":"Chem Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1158\/1535-7163.MCT-08-0130","article-title":"Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia.","volume":"7","author":"CJ Chou","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/nar\/gkl1025","article-title":"Unanticipated differences between {alpha}- and {gamma}-diaminobutyric acid-linked hairpin polyamide-alkylator conjugates.","volume":"35","author":"SM Tsai","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1016\/j.bmc.2007.07.019","article-title":"alpha-Diaminobutyric acid-linked hairpin polyamides.","volume":"15","author":"ME Farkas","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.4161\/cc.5.14.2913","article-title":"A two-hit mechanism for pre-mitotic arrest of cancer cell proliferation by a polyamide-alkylator conjugate.","volume":"5","author":"D Alvarez","year":"2006","journal-title":"Cell Cycle"},{"key":"ref24","first-page":"53","article-title":"A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.","volume":"4","author":"GR Weiss","year":"1998","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/1078-0432.CCR-0658-03","article-title":"A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.","volume":"10","author":"AC Lockhart","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0301-472X(01)00633-6","article-title":"Novel therapies for chronic myelogenous leukemia.","volume":"29","author":"BN Jahagirdar","year":"2001","journal-title":"Exp Hematol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.","volume":"1","author":"R Capdeville","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2402889","article-title":"Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.","volume":"17","author":"N von Bubnoff","year":"2003","journal-title":"Leukemia"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00001622-200211000-00005","article-title":"Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.","volume":"14","author":"R Nimmanapalli","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"vi42","DOI":"10.1093\/annonc\/mdm223","article-title":"Dasatinib: a new step in molecular target therapy.","volume":"18","author":"A Olivieri","year":"2007","journal-title":"Ann Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1073\/pnas.0800587105","article-title":"SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.","volume":"105","author":"T O'Hare","year":"2008","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0003593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T18:10:36Z","timestamp":1540231836000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0003593"}},"subtitle":[],"editor":[{"given":"Floyd","family":"Romesberg","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2008,10,31]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2008,10,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0003593","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,31]]}}}